upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | Health Care | Pharmaceuticals | 56.19 |
19.8
35.5
31.5
|
3-month |
0 / 15
|
|
0 / 166465
|
0.0 / 0.3 |
| 6-month |
0 / 26
|
|
0 / 218053
|
0.0 / 0.4 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Celgene Corp /De/ | 10% Owner | 2019-11-14 | 12.7% | 7121658 (6.0%, NA%) | 6718433 (2018-01-31) | ||
| Celgene European Investment Co Llc | 10% Owner | 2017-04-24 | 10.4% | 5867279 (11.9%, NA%) | 5242704 (2014-12-17) | ||
| Arch Venture Fund Vii Lp | 10% Owner | 2015-02-23 | 5.5% | 3088590 (-11.0%, NA%) | 3474664 (2014-06-25) | ||
| Flagship Ventures Fund 2007, L.P. | 10% Owner | 2014-06-25 | 3.4% | 1930369 (NA%, NA%) | () | ||
| Schenkein David P | Director | 2024-02-29 | 0.8% | 472708 (0.0%, 0.0%) | 472708 (2024-02-27) |
C: 0 / 2
S: 0 / 137471 P: NA / 33.89 |
C: 0 / 2
S: 0 / 137471 P: NA / 33.89 |
| Cantley Lewis Clayton Jr. | Director | 2017-12-08 | 0.4% | 200596 (-1.8%, NA%) | 204434 (2017-11-15) | ||
| Starr Kevin P | Director, 10% Owner | 2015-02-19 | 0.3% | 184386 (-93.9%, NA%) | 3096609 (2014-09-12) | ||
| Fouse Jacqualyn A | Director | 2024-04-10 | 0.2% | 137396 (6.3%, 6.3%) | 129253 (2024-01-24) |
C: 0 / 1
S: 0 / 7791 P: NA / 27.55 |
C: 0 / 3
S: 0 / 26904 P: NA / 23.77 |
| Higgons John Duncan | Chief Operating Officer | 2016-01-05 | 0.2% | 120834 (95.4%, NA%) | 61835 (2015-12-17) | ||
| Nelsen Robert | Director | 2017-03-07 | 0.2% | 109230 (-27.0%, NA%) | 149829 (2017-03-01) | ||
| Goff Brian | CEO | 2024-03-05 | 0.1% | 53780 (8.8%, 8.8%) | 49436 (2024-01-24) |
C: 0 / 1
S: 0 / 4156 P: NA / 32.57 |
C: 0 / 3
S: 0 / 23857 P: NA / 24.23 |
| Gheuens Sarah | Chief Medical Officer | 2024-03-05 | 0.1% | 39066 (16.9%, 22.4%) | 33431 (2024-02-14) |
C: 0 / 2
S: 0 / 3284 P: NA / 31.12 |
C: 0 / 4
S: 0 / 6781 P: NA / 26.59 |
| Burns James William | Chief Legal Officer | 2024-03-05 | 0.1% | 37169 (17.4%, 22.4%) | 31666 (2024-02-14) |
C: 0 / 2
S: 0 / 3187 P: NA / 31.3 |
C: 0 / 4
S: 0 / 6058 P: NA / 26.98 |
| Jones Cecilia | Chief Financial Officer | 2024-03-05 | 0.0% | 14840 (13.6%, 13.6%) | 13069 (2024-01-24) |
C: 0 / 1
S: 0 / 672 P: NA / 32.57 |
C: 0 / 2
S: 0 / 2558 P: NA / 24.51 |
| Milanova Tsveta | Chief Commercial Officer | 2024-01-24 | 0.0% | 13234 (40.7%, NA%) | 9404 (2024-01-05) |
C: 0 / 2
S: 0 / 4520 P: NA / 22.08 |
|
| Scadden David | Director | 2023-06-23 | 0.0% | 12095 (69.9%, NA%) | 7120 (2022-05-24) | ||
| Ho Maykin | Director | 2023-06-23 | 0.0% | 11524 (76.0%, NA%) | 6549 (2022-05-24) | ||
| Foster Cheek Kaye I | Director | 2024-03-11 | 0.0% | 7724 (-14.2%, -43.6%) | 9009 (2024-03-07) |
C: 0 / 2
S: 0 / 6000 P: NA / 31.92 |
C: 0 / 2
S: 0 / 6000 P: NA / 31.92 |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-10 | 2024-04-08 | 2024-04-10 | 4 | Fouse Jacqualyn A | DIRECTOR | dsp | 7791.0 | 5.37 | 1.39 | 27.55 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 137396.0 | 56.19 (AGIO) |
| 2024-04-10 | 2024-04-08 | 2024-04-08 | 4 | Fouse Jacqualyn A | DIRECTOR | acq | 15934.0 | 10.97 | 2.84 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 145187.0 | 56.19 (AGIO) |
| 2024-03-11 | 2024-03-07 | 4 | Foster Cheek Kaye I | DIRECTOR | holding | 2200.0 | 0 | 0.39 | 0.0 | By Foster Family Revocable Trust | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Foster Cheek Kaye I | DIRECTOR | dsp | 1285.0 | 18.87 | 0.23 | 31.62 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 5524.0 | 56.19 (AGIO) |
| 2024-03-07 | 2024-03-05 | 2024-03-05 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | dsp | 1913.0 | 39.86 | 0.34 | 31.75 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 2886.0 | 56.19 (AGIO) |
| 2024-03-07 | 2024-03-05 | 4 | Foster Cheek Kaye I | DIRECTOR | holding | 2200.0 | 0 | 0.39 | 0.0 | By Foster Family Revocable Trust | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-03-07 | 2024-03-05 | 2024-03-05 to 2024-03-06 | 4 | Foster Cheek Kaye I | DIRECTOR | dsp | 4715.0 | 40.91 | 0.84 | 32.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 6809.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-05 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 2642.0 | 6.64 | 0.47 | 32.57 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 37169.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Burns James William | CHIEF LEGAL OFFICER | acq | 7834.0 | 20.34 | 1.39 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 38518.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-05 | 4 | Goff Brian | CEO | dsp | 4156.0 | 7.17 | 0.74 | 32.57 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 53780.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Goff Brian | CEO | acq | 8500.0 | 14.67 | 1.51 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 57936.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | acq | 2000.0 | 12.89 | 0.36 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 15512.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-05 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | dsp | 672.0 | 4.33 | 0.12 | 32.57 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 14840.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | acq | 7834.0 | 19.38 | 1.39 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 40415.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-05 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | dsp | 2642.0 | 6.33 | 0.47 | 32.57 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 39066.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | acq | 3127.0 | 54.69 | 0.56 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 5718.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-05 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | dsp | 1214.0 | 20.19 | 0.22 | 32.57 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 4799.0
|
56.19 (AGIO) |
| 2024-02-29 | 2024-02-27 | 2024-02-27 | 4 | Schenkein David P | DIRECTOR | acq | 69329.0 | 38.45 | 12.34 | 31.64 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 180325.0
|
56.19 (AGIO) |
| 2024-02-29 | 2024-02-27 | 2024-02-27 | 4 | Schenkein David P | DIRECTOR | dsp | 69329.0 | 36.07 | 12.34 | 34.67 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 122854.0
|
56.19 (AGIO) |
| 2024-02-29 | 2024-02-27 | 4 | Schenkein David P | DIRECTOR | holding | 270772.0 | 0 | 48.18 | 0.0 | David P | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-02-29 | 2024-02-27 | 4 | Schenkein David P | DIRECTOR | holding | 79082.0 | 0 | 14.07 | 0.0 | Amy P | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-02-27 | 2024-02-23 | 4 | Schenkein David P | DIRECTOR | holding | 270772.0 | 0 | 48.18 | 0.0 | David P | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-02-27 | 2024-02-23 | 4 | Schenkein David P | DIRECTOR | holding | 79082.0 | 0 | 14.07 | 0.0 | Amy P | Common Stock | AGIOS PHARMACEUTICALS, INC. | NA | 56.19 (AGIO) | ||
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Schenkein David P | DIRECTOR | acq | 68142.0 | 47.56 | 12.13 | 31.64 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 143265.0
|
56.19 (AGIO) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Schenkein David P | DIRECTOR | dsp | 68142.0 | 35.68 | 12.13 | 33.09 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 122854.0
|
56.19 (AGIO) |
| 2024-02-22 | 2024-02-20 | 2024-02-20 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | dsp | 504.0 | 15.53 | 0.09 | 26.63 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 2741.0 | 56.19 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-14 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | dsp | 642.0 | 1.88 | 0.11 | 25.14 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 33431.0 | 55.89 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-12 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | acq | 2162.0 | 6.35 | 0.39 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 34073.0 | 55.89 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-14 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 545.0 | 1.69 | 0.1 | 25.14 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code S | 31666.0 | 55.89 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-12 | 4 | Burns James William | CHIEF LEGAL OFFICER | acq | 1833.0 | 5.69 | 0.33 | 0.0 | Direct | Common Stock | AGIOS PHARMACEUTICALS, INC. | code M | 32211.0 | 55.89 (AGIO) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-10 | 2024-04-08 | 2024-04-08 | 4 | Fouse Jacqualyn A | DIRECTOR | dsp | 15934.0 | 50.0 | 2.84 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 15933.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Milanova Tsveta | CHIEF COMMERCIAL OFFICER | acq | 17000.0 | 100.0 | 3.03 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 17000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Milanova Tsveta | CHIEF COMMERCIAL OFFICER | acq | 60000.0 | 100.0 | 10.68 | 32.27 | Direct | Stock Options (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code A | 60000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Burns James William | CHIEF LEGAL OFFICER | acq | 60000.0 | 100.0 | 10.68 | 32.27 | Direct | Stock Options (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code A | 60000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 7834.0 | 49.48 | 1.39 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 8000.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Burns James William | CHIEF LEGAL OFFICER | acq | 17000.0 | 100.0 | 3.03 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 17000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Goff Brian | CEO | dsp | 8500.0 | 33.33 | 1.51 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 17000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Goff Brian | CEO | acq | 54000.0 | 100.0 | 9.61 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 54000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Goff Brian | CEO | acq | 195500.0 | 100.0 | 34.79 | 32.27 | Direct | Stock Options (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code A | 195500.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | acq | 17000.0 | 100.0 | 3.03 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 17000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | dsp | 2000.0 | 33.33 | 0.36 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 4000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | acq | 60000.0 | 100.0 | 10.68 | 32.27 | Direct | Stock Options (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code A | 60000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | acq | 60000.0 | 100.0 | 10.68 | 32.27 | Direct | Stock Options (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code A | 60000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | acq | 17000.0 | 100.0 | 3.03 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 17000.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | dsp | 7834.0 | 49.48 | 1.39 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 8000.0
|
56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | acq | 7350.0 | 100.0 | 1.31 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code A | 7350.0 | 56.19 (AGIO) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | dsp | 3127.0 | 39.95 | 0.56 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 4700.0
|
56.19 (AGIO) |
| 2024-02-29 | 2024-02-27 | 2024-02-27 | 4 | Schenkein David P | DIRECTOR | dsp | 69329.0 | 100.0 | 12.34 | 31.64 | Direct | Stock Option (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code M | 0.0
|
56.19 (AGIO) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Schenkein David P | DIRECTOR | dsp | 68142.0 | 49.57 | 12.13 | 31.64 | Direct | Stock Option (Right To Buy) | AGIOS PHARMACEUTICALS, INC. | code M | 69329.0
|
56.19 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-12 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | dsp | 2162.0 | 100.0 | 0.39 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-12 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 1833.0 | 100.0 | 0.33 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-02-14 | 2024-02-12 | 2024-02-12 | 4 | Washburn Theodore James Jr. | PRINCIPAL ACCOUNTING OFFICER | dsp | 777.0 | 100.0 | 0.14 | 0.0 | Direct | Restricted Stock Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Jones Cecilia | CHIEF FINANCIAL OFFICER | dsp | 5380.0 | 100.0 | 0.96 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 5750.0 | 100.0 | 1.03 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Fouse Jacqualyn A | DIRECTOR | dsp | 23900.0 | 100.0 | 4.28 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Goff Brian | CEO | dsp | 17018.0 | 14.29 | 3.04 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 102110.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Gheuens Sarah | CHIEF MEDICAL OFFICER | dsp | 5750.0 | 100.0 | 1.03 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-24 | 2024-01-20 | 2024-01-20 | 4 | Milanova Tsveta | CHIEF COMMERCIAL OFFICER | dsp | 5448.0 | 100.0 | 0.97 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
| 2024-01-09 | 2024-01-05 | 2024-01-05 | 4 | Goff Brian | CEO | dsp | 25527.0 | 17.65 | 4.57 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 119128.0 | 55.89 (AGIO) |
| 2024-01-09 | 2024-01-05 | 2024-01-05 | 4 | Burns James William | CHIEF LEGAL OFFICER | dsp | 3250.0 | 100.0 | 0.58 | 0.0 | Direct | Performance Share Units | AGIOS PHARMACEUTICALS, INC. | code M | 0.0 | 55.89 (AGIO) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)